SB 203580

• CAT Number: I001888
• CAS Number: 152121-47-6
• Molecular Formula: C₂₁H₁₆FN₃OS
• Molecular Weight: 377.43
• Purity: ≥95%
• Target: p38
• Solubility: DMSO: ≥ 33 mg/mL
• Storage: 3 years -20C powder
• IC50: 0.3 -0.5 uM
• InChI: InChI=1S/C21H16FN3OS/c1-27(26)18-8-4-16(5-9-18)21-24-19(14-2-6-17(22)7-3-14)20(25-21)15-10-12-23-13-11-15/h2-13H,1H3,(H,24,25)
• InChIKey: CDMGBJANTYXAIV-UHFFFAOYSA-N
• SMILES: CS(=O)C1=CC=C(C=C1)C2=NC(=C(N2)C3=CC=NC=C3)C4=CC=C(C=C4)F

SB203580 (CAT: I001888) is a potent inhibitor of p38 mitogen-activated protein kinase (MAPK) with an IC50 ranging from 0.3 to 0.5 μM. By targeting p38 MAPK, SB203580 disrupts the signaling pathway involved in cellular responses to stress and inflammation. It effectively interferes with the activation of p38 MAPK, which plays a crucial role in mediating various cellular processes, including cytokine production, cell differentiation, and apoptosis. Additionally, SB203580 has been shown to impact protein kinase B (PKB) phosphorylation, requiring an IC50 of 3-5 μM.

Reference

1:A Single Amino Acid Substitution Makes WNK4 Susceptible to SB 203580 and SB 202190. Glover M, Sweeny C, Davis B, O/’Shaughnessy KM.Open Med Chem J. 2010 Sep 3;4:57-61. doi: 10.2174/1874104501004010057. PMID: 21249167 Free PMC Article2:Non-specific in vivo inhibition of CK1 by the pyridinyl imidazole p38 inhibitors SB 203580 and SB 202190. Shanware NP, Williams LM, Bowler MJ, Tibbetts RS.BMB Rep. 2009 Mar 31;42(3):142-7. PMID: 19336000 Free PMC Article3:Temporary blockade of contractility during reperfusion elicits a cardioprotective effect of the p38 MAP kinase inhibitor SB-203580. Sumida T, Otani H, Kyoi S, Okada T, Fujiwara H, Nakao Y, Kido M, Imamura H.Am J Physiol Heart Circ Physiol. 2005 Jun;288(6):H2726-34. Epub 2005 Feb 4. PMID: 15695561 Free Article4:Regulation of the circadian oscillator in Xenopus retinal photoreceptors by protein kinases sensitive to the stress-activated protein kinase inhibitor, SB 203580. Hasegawa M, Cahill GM.J Biol Chem. 2004 May 21;279(21):22738-46. Epub 2004 Mar 17. PMID: 15028715 Free Article5:Defining the involvement of p38alpha MAPK in the production of anti- and proinflammatory cytokines using an SB 203580-resistant form of the kinase. Guo X, Gerl RE, Schrader JW.J Biol Chem. 2003 Jun 20;278(25):22237-42. Epub 2003 Mar 11. PMID: 12637577 Free Article6:Stress-induced regulation of eukaryotic elongation factor 2 kinase by SB 203580-sensitive and -insensitive pathways. Knebel A, Haydon CE, Morrice N, Cohen P.Biochem J. 2002 Oct 15;367(Pt 2):525-32. PMID: 12171600 Free PMC Article7:Dichotomal role of inhibition of p38 MAPK with SB 203580 in experimental colitis. ten Hove T, van den Blink B, Pronk I, Drillenburg P, Peppelenbosch MP, van Deventer SJ.Gut. 2002 Apr;50(4):507-12. PMID: 11889071 Free PMC Article8:Preclinical pharmacokinetics of SB-203580, a potent inhibitor of p38 mitogen-activated protein kinase. Ward KW, Prokscht JW, Azzaranot LM, Mumawa JA, Roethke TJ, Stelman GJ, Walsh MJ, Zeigler KS, McSurdy-Freed JE, Kehlert JR, Chokshi J, Levy MA, Smith BR.Xenobiotica. 2001 Nov;31(11):783-97. PMID: 11765141 9:Inhibition of caspase-3 activation by SB 203580, p38 mitogen-activated protein kinase inhibitor in nitric oxide-induced apoptosis of PC-12 cells. Sarker KP, Nakata M, Kitajima I, Nakajima T, Maruyama I.J Mol Neurosci. 2000 Dec;15(3):243-50. PMID: 11303787 10:SB 203580, an inhibitor of p38 MAPK, abolishes infarct-limiting effect of ischemic preconditioning in isolated rabbit hearts. Nakano A, Cohen MV, Critz S, Downey JM.Basic Res Cardiol. 2000 Dec;95(6):466-71. PMID: 11192367